Skip to main navigation Skip to search Skip to main content

Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region

    • Pfizer
    • Mediclinic City Hospital

    Project: Clinical Trial

    Project Details

    Description

    Retrospective non-interventional study (NIS) that aims to describe the demographics, clinical characteristics, clinical outcomes, and treatment patterns, among patients receiving palbociclib for the treatment of HR+/HER2- metastatic/locally advanced breast cancer (BC).
    StatusFinished
    Effective start/end date13/09/2127/12/22

    Collaborative partners

    Keywords

    • Retrospective Studies
    • Palbociclib
    • Neoplasms by Site
    • Neoplasms
    • Breast Diseases
    • Skin Diseases
    • Breast Neoplasms
    • Hormonal Antineoplastic Agents
    • Antineoplastic Agents
    • Estrogen Receptor Antagonists
    • Estrogen Antagonists
    • Hormone Antagonists
    • Hormones
    • Hormone Substitutes
    • Physiological Effects of Drugs
    • Protein Kinase Inhibitors
    • Enzyme Inhibitors
    • Molecular Mechanisms of Pharmacological Action
    • Steroid Synthesis Inhibitors
    • Fulvestrant
    • Aromatase Inhibitors

    Fingerprint

    Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.